Filter Results
:
(723)
Show Results For
-
All HBS Web
(1,926)
- Faculty Publications (723)
Show Results For
-
All HBS Web
(1,926)
- Faculty Publications (723)
- June 2023
- Supplement
Roche: ESG and Access to Healthcare
By: George Serafeim
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Health Industry;
Pharmaceutical Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George. "Roche: ESG and Access to Healthcare." Harvard Business School Multimedia/Video Supplement 123-713, June 2023.
- June 2023 (Revised July 2023)
- Case
Social Media Background Screening at Fama Technologies
By: Joseph Pacelli, Jillian Grennan and Alexis Lefort
Fama Technologies is an online screening company that uses AI to analyze job applicants' publicly available online content for signs of risk and culture fit. The case opens with Ben Mones, founder and CEO, looking to secure funding from venture firms. He is running...
View Details
Keywords:
Human Resources;
Recruitment;
Retention;
Selection and Staffing;
Organizational Culture;
Talent and Talent Management;
AI and Machine Learning;
Social Media;
Venture Capital;
Entrepreneurship;
United States
Pacelli, Joseph, Jillian Grennan, and Alexis Lefort. "Social Media Background Screening at Fama Technologies." Harvard Business School Case 123-010, June 2023. (Revised July 2023.)
- June 2023
- Case
Investing in the Climate Transition at Neuberger Berman
By: George Serafeim and Benjamin Maletta
By mid-2023, Neuberger Berman (NB), an active asset manager, had grown its assets under management to about half a trillion dollars and took pride in its client centricity and innovative spirit. Responding to client demand for investment products that integrated...
View Details
Keywords:
Carbon Emissions;
Sustainability;
Decarbonization;
Performance;
Risk Assessment;
Opportunities;
Environmental Sustainability;
Carbon Footprint;
Business Analysis;
Investing;
Regulation;
Asset Management;
Investment Strategy;
Climate Change;
Transition;
Analysis;
Product Positioning;
Strategy;
Investment Portfolio;
Financial Services Industry;
Energy Industry
- June 2023
- Article
Regulatory Limits to Risk Management
By: Ishita Sen
Variable annuities, the largest liability of U.S. life insurers, are investment products containing long-dated minimum return guarantees. I show that guarantees with similar economic risks are treated differently by regulation and these differences impact insurers’...
View Details
Keywords:
Interest Rate Risk;
Variable Annuities;
Capital Regulation;
Reinsurance;
Derivatives;
Risk Management;
Interest Rates;
Governing Rules, Regulations, and Reforms
Sen, Ishita. "Regulatory Limits to Risk Management." Review of Financial Studies 36, no. 6 (June 2023): 2175–2223.
- May 2023
- Technical Note
Dynamic Pricing: Timing is Everything
By: Elie Ofek
This note provides a comprehensive exposition to the topic of dynamic pricing (whereby the fee customers are charged is time-dependent). It covers the motivation for firms to engage in dynamic pricing, provides a typology of the main formats dynamic pricing can take,...
View Details
Ofek, Elie. "Dynamic Pricing: Timing is Everything." Harvard Business School Technical Note 523-110, May 2023.
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an...
View Details
Keywords:
Finance;
Strategy;
Capital Allocation;
Biopharmaceutical Industry;
Shareholder Activism;
Investment Activism;
Resource Allocation;
Research and Development;
Business and Shareholder Relations;
Corporate Strategy;
Pharmaceutical Industry
Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.
- April 2023
- Case
Strive Asset Management
By: Suraj Srinivasan, Lynn S. Paine and Aldo Sesia
Strive Asset Management, which launched in 2022, was actively targeting several leading U.S. companies in the upcoming 2023 proxy voting season to stop acquiescing to those large asset managers and other institutional shareholders who were pressing those companies to...
View Details
- March 2023
- Supplement
Allianz Türkiye (C): Managing the 2017 Hail Storm
By: John D. Macomber and Fares Khrais
Allianz Turkey is a property casualty insurance company operating in a region experiencing increasing losses from natural catastrophe events related to climate change, for example hail, wildfire, and flooding. There are also substantial other natural catastrophe...
View Details
- March 2023 (Revised March 2023)
- Case
Allianz Türkiye: Adapting to Climate Change
By: John D. Macomber and Fares Khrais
Allianz Turkey is a property casualty insurance company operating in a region experiencing increasing losses from natural catastrophe events related to climate change, for example hail, wildfire, and flooding. There are also substantial other natural catastrophe...
View Details
- March 2023
- Case
Roche: ESG and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Health Industry;
Pharmaceutical Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: ESG and Access to Healthcare." Harvard Business School Case 123-075, March 2023.
- February 2023
- Article
Climate Solutions Investments
By: Alex Cheema-Fox, George Serafeim and Hui (Stacie) Wang
An increasing number of companies are providing products and services that help reduce carbon emissions in the economy. We develop a methodology to identify those companies and create a sample of publicly listed climate solutions companies allowing us to study their...
View Details
Keywords:
Decarbonization;
Climate Finance;
Climate Impact;
Climate Risk;
Environment;
Sustainability;
Carbon Emissions;
Electric Vehicles;
Energy;
Renewables;
Climate Change;
Corporate Social Responsibility and Impact;
Environmental Sustainability;
Emerging Markets;
Investment Portfolio
Cheema-Fox, Alex, George Serafeim, and Hui (Stacie) Wang. "Climate Solutions Investments." Journal of Portfolio Management 49, no. 3 (February 2023): 72–96.
- February 2023
- Article
OTC Intermediaries
By: Andrea L. Eisfeldt, Bernard Herskovic, Sriram Rajan and Emil Siriwardane
We study the effect of dealer exit on prices and quantities in a model of an over-the-counter (OTC) market featuring a core-periphery network with bilateral trading costs. The model is calibrated using regulatory data on the entire U.S. credit default swap (CDS) market...
View Details
Keywords:
OTC Markets;
Intermediaries;
Dealers;
Credit Default Swaps;
Risk Sharing;
Financial Markets;
Networks;
Price;
Risk and Uncertainty
Eisfeldt, Andrea L., Bernard Herskovic, Sriram Rajan, and Emil Siriwardane. "OTC Intermediaries." Review of Financial Studies 36, no. 2 (February 2023): 615–677.
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged...
View Details
Keywords:
Opioids;
Shareholder Activism;
Investment Activism;
Corporate Accountability;
Corporate Governance;
Governance Compliance;
Governance Controls;
Executive Compensation;
Risk Management;
Corporate Social Responsibility and Impact;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Distribution Industry;
Health Industry;
Pharmaceutical Industry;
United States;
West Virginia;
Tennessee;
Ohio;
Pennsylvania
- January 2023
- Supplement
The END Fund (B)
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Health Disorders;
Investment Funds;
Global Range;
Nonprofit Organizations;
Resource Allocation;
Decisions;
Health Care and Treatment;
Mission and Purpose
Rangan, V. Kasturi, and Courtney Han. "The END Fund (B)." Harvard Business School Supplement 523-064, January 2023.
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Nonprofit Organizations;
Health Disorders;
Health Care and Treatment;
Resource Allocation;
Global Range;
Decisions;
Investment Funds
Rangan, V. Kasturi, and Courtney Han. "The END Fund: To Eliminate Neglected Tropical Diseases." Harvard Business School Case 523-063, January 2023.
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful...
View Details
Keywords:
Product Development;
Leadership;
Health Testing and Trials;
Research and Development;
Risk and Uncertainty;
Financial Condition;
Partners and Partnerships;
Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- January 2023
- Case
Thomas Buberl: Refounding AXA
By: Hubert Joly, Mihir Desai and Amram Migdal
In 2022, AXA and its CEO Thomas Buberl faced new types of challenges, including systemic risks such as climate change, geopolitical instability, public health crises, and social tensions caused by economic risks. AXA was one of the world’s largest insurers. Since...
View Details
Keywords:
Change;
Change Management;
Transformation;
Transition;
Trends;
Environmental Management;
Climate Change;
Ethics;
Values and Beliefs;
Finance;
Insurance;
Management;
Management Succession;
Risk Management;
Organizations;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Organizational Change and Adaptation;
Planning;
Strategic Planning;
Risk and Uncertainty;
Society;
Human Needs;
Social Issues;
Strategy;
Adaptation;
Business Strategy;
Corporate Strategy;
Insurance Industry;
Europe;
France;
Paris
Joly, Hubert, Mihir Desai, and Amram Migdal. "Thomas Buberl: Refounding AXA." Harvard Business School Case 523-059, January 2023.
- 2023
- Working Paper
Public Perception and Autonomous Vehicle Liability
By: Julian De Freitas, Xilin Zhou, Margherita Atzei, Shoshana Boardman and Luigi Di Lillo
The deployment of autonomous vehicles (AVs) and the accompanying societal and economic benefits will greatly depend on how much liability AV firms will have to carry for accidents involving these vehicles, which in turn impacts their insurability and associated...
View Details
Keywords:
Autonomous Vehicles;
Moral Judgment;
Liabilities;
Harm;
Insurance;
Moral Sensibility;
Legal Liability;
Risk and Uncertainty;
Technological Innovation;
Public Opinion
De Freitas, Julian, Xilin Zhou, Margherita Atzei, Shoshana Boardman, and Luigi Di Lillo. "Public Perception and Autonomous Vehicle Liability." Harvard Business School Working Paper, No. 23-036, January 2023. (Revised January 2023.)
- 2023
- Working Paper
The Evolving Academic Field of Climate Finance
By: Matteo Gasparini and Peter Tufano
The urgency and the magnitude of climate change will affect every aspect of our economies, societies, and planet. The academic finance research has begun to study the financial implications of global warming, although this body of literature is small. The field has...
View Details
Keywords:
Climate Finance;
Finance Academia;
Greenhouse Gas;
Sustainable Finance;
Financial Decisions;
Educational Finance;
Finance;
Climate Change;
Transition
Gasparini, Matteo, and Peter Tufano. "The Evolving Academic Field of Climate Finance." Harvard Business School Working Paper, No. 23-057, January 2023.
- December 2022
- Case
To Feed the Planet: Juan Luciano at ADM
By: Joshua D. Margolis, David E. Bell, Damien McLoughlin, Stacy Straaberg and James Weber
In December 2022, Juan Luciano, Chairman and CEO of agribusiness and nutrition giant ADM, considered the next phase of the historic company’s future. Beginning in 2011 when he joined as COO and moving into his tenure as CEO in 2015, Luciano led a transformation of ADM...
View Details
Keywords:
Agriculture;
Leadership;
Agribusiness;
Acquisition;
Business Units;
Customer Focus and Relationships;
Customer Value and Value Chain;
Forecasting and Prediction;
Capital;
Cash;
Cost of Capital;
Cost Management;
Profit;
Food;
Global Range;
Innovation Strategy;
Leadership Development;
Leadership Style;
Leading Change;
Growth and Development Strategy;
Risk Management;
Organizational Culture;
Organizational Structure;
Strategic Planning;
Risk and Uncertainty;
Adaptation;
Business Strategy;
Corporate Strategy;
Vertical Integration;
Value Creation;
Transformation;
Agriculture and Agribusiness Industry;
Energy Industry;
United States;
Chicago
Margolis, Joshua D., David E. Bell, Damien McLoughlin, Stacy Straaberg, and James Weber. "To Feed the Planet: Juan Luciano at ADM." Harvard Business School Case 423-060, December 2022.